Tissue Regeneration by Engineered Extracellular Vesicles

总结 全球干细胞治疗市场有望以39.5%的复合年增长率（CAGR）增长 从2015年到2020年，到2020年达到3.3亿美元。然而，局限性，如：（1）有关的道德问题， 胚胎干细胞，（2）与保存干细胞相关的困难，以及（3）最近的研究 研究发现，干细胞对再生组织的结构贡献实际上非常小， 开始损害基于干细胞疗法的承诺潜力。最近的研究表明， 从基于细胞的治疗转移到旁分泌假说，研究刺激因素 由细胞释放和接收的，包括：生长因子、细胞因子和细胞外囊泡（EV;即， 含有血管生成因子、转录因子、miRNA的外来体和微泡）。工作提出的 这里将确定是否骨髓细胞，即，可以被工程化以分化（或转分化）成 通过在我们的新系统中精心策划的EV交换工程， 生物材料平台

Summary Worldwide stem cell therapy market is poised to grow at a compound annual growth rate (CAGR) of 39.5% from 2015 to 2020, reaching US$330M by 2020. However, limitations such as: (1) ethical issues related to embryonic stem cells, (2) difficulties related with the preservation of stem cells, and (3) recent research findings that the structural contribution of stem cells to regenerated tissues is actually very small, are starting to compromise the promised potential of stem-cell based therapies. Recent research has thus shifted away from cell based therapy to a paracrine hypothesis, investigating the stimulating factors released and received by cells, including: growth factors, cytokines, and extracellular vesicles (EVs; i.e., exosomes and microvesicles containing angiogenic factors, transcription factors, miRNAs). Work proposed here will determine whether myeloid cells, i.e., can be engineered to differentiate (or trans-differentiate) into desired non-myeloid lineages through an orchestrated engineering of EV exchange within our novel biomaterials platform.